On Thursday 9 July 2026, Roche announced the discontinuation of two EHDN-endorsed studies:

• GENERATION HD2 (clinicaltrials.gov/study/NCT05686551): A phase 2/open-label extension study of tominersen compared with placebo in Huntington’s disease (HD).
• POINT-HD (clinicaltrials.gov/study/NCT07246941): A phase 1 study of RG6496 delivered intrathecally compared with placebo in HD.

The community letter from Roche can be read in full here.

We share the disappointment of the HD community and will shortly issue a full statement from the EHDN Executive Committee via our usual channels.

We remain grateful for the unwavering generosity and commitment of the HD community to taking part in research and, in doing so, advancing our understanding of HD.